Helen Moon

1.1k total citations
27 papers, 189 citations indexed

About

Helen Moon is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Helen Moon has authored 27 papers receiving a total of 189 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 18 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Helen Moon's work include Bladder and Urothelial Cancer Treatments (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Urinary and Genital Oncology Studies (8 papers). Helen Moon is often cited by papers focused on Bladder and Urothelial Cancer Treatments (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Urinary and Genital Oncology Studies (8 papers). Helen Moon collaborates with scholars based in United States, France and Spain. Helen Moon's co-authors include Adam T. Perzynski, R. Tyler Miller, Yang Liu, Brook Watts, Paul E. Drawz, Rana R. McKay, Yao Yu, Peter H. O’Donnell, Jonathan E. Rosenberg and Terence W. Friedlander and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Helen Moon

23 papers receiving 185 citations

Peers

Countries citing papers authored by Helen Moon

Since Specialization

Citations

This map shows the geographic impact of Helen Moon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Moon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Moon more than expected).

Fields of papers citing papers by Helen Moon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Moon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Moon. The network helps show where Helen Moon may publish in the future.

Co-authorship network of co-authors of Helen Moon

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Moon. A scholar is included among the top collaborators of Helen Moon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Moon. Helen Moon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y 2025 ·Annals of Oncology ·Terence W. Friedlander, Peter H. O’Donnell, (unknown), Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar, Helen Moon, Rana R. McKay, (unknown), Saby George, Jason R. Brown, Mehmet Asım Bilen, Delphine Borchiellini, Marco Iafolla, Abhishek Bavle, M. C. Mihm, Y. Zhu, Changting Meng, Jacob Rosenberg	0
2	Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy 2025 ·Urologic Oncology Seminars and Original Investigations ·Helen Moon, Jeanny B. Aragon‐Ching, Allison Thompson, (unknown), Anna Vlahiotis, (unknown), (unknown), (unknown), Haiyan Sun, Mairead Kearney, (unknown), (unknown), Benjamin Li, (unknown), Petros Grivas	0
3	Prospective monitoring of prostate specific membrane antigen–positive biochemically recurrent prostate cancer (PSMA+ BCR): Preliminary data from 6-month PSMA follow-up. 2025 ·Journal of Clinical Oncology ·Ravi A. Madan, Melissa L. Abel, Esther Mena, Liza Lindenberg, (unknown), Monique Williams, Amy Hankin, Jeanny B. Aragon‐Ching, Laura A. Sena, Russell K. Pachynski, Edwin M. Posadas, Helen Moon, Marijo Bilušić, Fatima Karzai, Peter L. Choyke	0
4	Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States 2024 ·Current Oncology ·Helen Moon, Mairead Kearney, Seyed Hamidreza Mahmoudpour, (unknown), Valerie Morris, (unknown), Sonia Kim, Haiyan Sun, Marley Boyd, (unknown)	3
5	A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer 2024 ·Clinical Cancer Research ·Randy F. Sweis, Gurkamal Chatta, (unknown), Helen Moon, Scott E. Delacroix, (unknown), Leonard D’Amico, Angela Shaulov Kask, Martin A. Cheever, Steven P. Fling, Elad Sharon, Andreanne M. Lacroix, Judith C. Kaiser, Russell K. Pachynski, Evan Y. Yu	0
6	Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study 2024 ·The Lancet ·Toni K. Choueiri, Laurence Albigès, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina‐Cerrillo, Benjamin Garmezy, Pedro C. Barata, Arnab Basu, María T. Bourlon, Helen Moon, Raffaele Ratta, Rana R. McKay, Alex Chehrazi‐Raffle, Hans J. Hammers, Daniel Y.C. Heng, (unknown), Kathryn E. Beckermann, Bradley A. McGregor, Robert J. Motzer	32
7	Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study 2024 ·Clinical Genitourinary Cancer ·Petros Grivas, Pedro Barata, Helen Moon, Shilpa Gupta, (unknown), Cora N. Sternberg, Jason R. Brown, (unknown), (unknown), Alicia C. Shillington, Howard M. Katzenstein, (unknown), (unknown), (unknown), Valerie Morris, (unknown), Guru Sonpavde	5
8	Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US. 2024 ·Journal of Clinical Oncology ·Helen Moon, Mairead Kearney, Seyed Hamidreza Mahmoudpour, (unknown), Valerie Morris, (unknown), Sonia Kim, Haiyan Sun, Marley Boyd, (unknown)	2
9	Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study. 2024 ·Journal of Clinical Oncology ·Petros Grivas, Pedro C. Barata, Helen Moon, Shilpa Gupta, Thomas E. Hutson, Cora N. Sternberg, Jason R. Brown, (unknown), (unknown), Alicia C. Shillington, Howard M. Katzenstein, (unknown), (unknown), (unknown), Valerie Morris, (unknown), Guru Sonpavde	6
10	2367P A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC) 2023 ·Annals of Oncology ·Russell K. Pachynski, Gurkamal Chatta, Rohit Jain, Helen Moon, Randy F. Sweis, (unknown), Fang Tian, Steven P. Fling, André Lacroix, Judith C. Kaiser, Elad Sharon, Evan Y. Yu	1
11	Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), Anna Vlahiotis, (unknown), (unknown), (unknown), Haiyan Sun, Mairead Kearney, (unknown), Benjamin Li, (unknown), Helen Moon	1
12	Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC). 2023 ·Journal of Clinical Oncology ·Helen Moon, Jeanny B. Aragon‐Ching, Allison Thompson, (unknown), Anna Vlahiotis, (unknown), (unknown), (unknown), Haiyan Sun, Mairead Kearney, (unknown), (unknown), Benjamin Li, (unknown), Petros Grivas	4
13	Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects 2023 ·Journal of Managed Care & Specialty Pharmacy ·Matthew R. Smith, Shahneen Sandhu, Daniel J. George, Kim Nguyen, Fred Saad, Antoine Thiery-Vuillemin, O. Ståhl, David Olmos, Daniel C. Danila, Rustem Gafanov, Elena Castro, Helen Moon, Anthony M. Joshua, Gary Mason, Byron M. Espina, Yan Liu, Angela Lopez‐Gitlitz, Peter Francis, Katherine B. Bevans, Karim Fizazi	2
14	Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K. 2023 ·Journal of Clinical Oncology ·Peter H. O’Donnell, Jonathan E. Rosenberg, Christopher Hoimes, Daniel P. Petrylak, Matthew I. Milowsky, Rana R. McKay, Sandy Srinivas, Terence W. Friedlander, Chethan Ramamurthy, Mehmet Asım Bilen, Earle F. Burgess, Nataliya Mar, Helen Moon, Daniel M. Geynisman, Saby George, Anne‐Sophie Carret, Yao Yu, M. I. Guseva, Blanca Homet Moreno, Thomas W. Flaig	6
15	Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study. 2023 ·Journal of Clinical Oncology ·Matthew I. Milowsky, Peter H. O’Donnell, Christopher Hoimes, Daniel P. Petrylak, Thomas W. Flaig, Helen Moon, Terence W. Friedlander, Nataliya Mar, Rana R. McKay, Sandy Srinivas, Gwénaëlle Gravis, Chethan Ramamurthy, Manojkumar Bupathi, Sergio Bracarda, Phoebe Wright, Anne‐Sophie Carret, Yao Yu, (unknown), Ritesh Kataria, Jonathan E. Rosenberg	14
16	LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) 2022 ·Annals of Oncology ·Jonathan E. Rosenberg, (unknown), Chethan Ramamurthy, Nataliya Mar, Rana R. McKay, Terence W. Friedlander, (unknown), Sergio Bracarda, Saby George, Helen Moon, Daniel M. Geynisman, Daniel P. Petrylak, Delphine Borchiellini, Earle F. Burgess, J.P. Maroto Rey, (unknown), Yao Yu, (unknown), Blanca Homet Moreno, Peter H. O’Donnell	30
17	582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD) 2021 ·Annals of Oncology ·Matthew R. Smith, Shahneen Sandhu, Daniel J. George, K.N. Chi, Fred Saad, Antoine Thiery-Vuillemin, O. Ståhl, David Olmos, Daniel C. Danila, Rustem Gafanov, Elena Castro, Helen Moon, Anthony M. Joshua, Gary Mason, Byron M. Espina, (unknown), Katherine B. Bevans, Angela Lopez‐Gitlitz, Peter Francis, Karim Fizazi	1
18	Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes 2020 ·The Permanente Journal ·(unknown), (unknown), Fang Niu, Helen Moon, Thach‐Giao Truong, Robert Cooper, Rita L. Hui	4
19	Immune-related adverse events (IrAE) of elderly patients (pts) receiving PD-1 or PDL-1 inhibitors (PDIs) in a community-oncology setting: The experience at Kaiser Permanente California. 2018 ·Journal of Clinical Oncology ·Thach‐Giao Truong, (unknown), (unknown), Fang Niu, Michele M. Spence, (unknown), Robert Cooper, Helen Moon, Rita L. Hui	3
20	A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial 2015 ·BMC Nephrology ·(unknown), Helen Moon, Yang Liu, R. Tyler Miller, Adam T. Perzynski, Brook Watts, Paul E. Drawz	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact